.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 9,421,265

« Back to Dashboard

Details for Patent: 9,421,265

Title:Aqueous pharmaceutical compositions containing borate-polyol complexes
Abstract: The present invention is directed to the provision of multi-dose, ophthalmic compositions. The compositions possess sufficient antimicrobial activity to satisfy USP preservative efficacy requirements, as well as similar preservative standards (e.g., EP and JP). The compositions include at two different polyols in conjunction with borate and a low concentration of benzalkonium chloride.
Inventor(s): Kabra; Bhagwati P. (Euless, TX)
Assignee: Alcon Research, LTD. (Fort Worth, TX)
Filing Date:Apr 20, 2015
Application Number:14/690,617
Claims:1. A multi-dose ophthalmic composition, comprising: a first polyol, the first polyol being selected from mannitol, sorbitol or a combination thereof; a second polyol, the second polyol being selected from propylene glycol, glycerine or a combination thereof; an effective amount of borate, the effective amount being less than about 0.5 w/v % of the overall composition; BAC as an anti-microbial preservative, the concentration of BAC in the composition being greater than 0.00001 w/v % but less than 0.0035 w/v %; a therapeutic agent; and water; wherein the composition is a suspension with the therapeutic agent and carboxyvinyl polymer as a suspending agent.

2. A composition as in claim 1 wherein the composition satisfies Ph. Eur. A, Ph. Eur. B or both.

3. A composition as in claim 1 wherein the concentration of the first polyol is at least 0.01 w/v % but is less than about 0.35 w/v %.

4. A composition as in claim 1 wherein concentration of the BAC is less than 0.0025 w/v % of the composition.

5. A composition as in claim 1 wherein concentration of the BAC is less than 0.0015 w/v % of the composition.

6. A composition as in claim 1 wherein the first polyol is mannitol and the second polyol is propylene glycol.

7. A composition as in claim 1 wherein the composition is substantially free of any preservatives other than benzalkonium chloride.

8. A composition as in claim 1 wherein the resistance provided by the composition to normalization of tear pH after instillation in the eye is less than 25 .mu.l of 1 M NaOH/mL of composition.

9. A composition as in claim 1 wherein the pH of the composition is from about 6.2 to about 7.7.

10. A composition as in claim 1 wherein the therapeutic agent is brinzolamide.

11. A composition as in claim 1 wherein the composition is free of any quinolone anti-infective or anti-biotic therapeutic agent.

12. A composition as in claim 1 wherein the suspension is redispersed with no more than 15 seconds of vigorous shaking.

13. A multi-dose ophthalmic composition, comprising: a first polyol, the first polyol being selected from mannitol, sorbitol or a combination thereof and wherein the concentration of the first polyol is at least 0.01 w/v % but no greater than 0.5 w/v %; a second polyol, the second polyol being selected from propylene glycol, glycerine or a combination thereof wherein the second polyol is at least about 0.1 but less than about 5 w/v % of the composition; an effective amount of borate, the effective amount being less than about 0.5 w/v % of the overall composition; therapeutic agent; BAC as an anti-microbial preservative, the concentration of BAC in the composition being greater than 0.00001 w/v % but less than 0.0035 w/v %; and water; wherein the composition is substantially free of any preservatives other than benzalkonium chloride and wherein the composition is a suspension with the therapeutic agent and carboxyvinyl polymer as a suspending agent.

14. A composition as in claim 13 wherein the resistance provided by the composition to normalization of tear pH after instillation in the eye is less than 15 .mu.l of 1 M NaOH/mL of composition.

15. A composition as in claim 13 wherein the viscosity of the suspension is greater than 20 cps but less than 500 cps with the viscosity of the suspension being measured at a high shear rate of 120 sec-1 at room temperature.

16. A composition as in claim 15 wherein the suspension is redispersed with no more than 15 seconds of vigorous shaking.

17. A composition as in claim 13 wherein the composition is free of any quinolone anti-infective or anti-biotic therapeutic agent.

18. A composition as in claim 13 wherein the composition is configured for administration to the eye of the mammal repeatedly for an extend period of time of and is administered at least once a week and wherein the eye of the mammal has been diagnosed with an eye disorder that is suitably treated with chronic administration of the therapeutic agent.

19. A composition as in claim 18 wherein the eye disorder is elevated intraocular pressure.

20. A multi-dose ophthalmic composition, comprising: mannitol wherein the concentration of the mannitol is at least 0.01 w/v % but no greater than 0.5 w/v %; propylene glycol wherein the concentration of the mannitol is at least 0.01 w/v % but no greater than 0.5 w/v %; an effective amount of borate, the effective amount being less than about 0.5 w/v % of the overall composition; therapeutic agent selected from brinzolamide, brimonidine or a combination thereof; carboxyvinyl polymer that is at least about 0.1 w/v % but less than about 1.2 w/v % of the composition; BAC as an anti-microbial preservative, the concentration of BAC in the composition being greater than 0.00001 w/v % but less than 0.0035 w/v %; and water; wherein: i. the composition is substantially free of any preservatives other than benzalkonium chloride; ii. the resistance provided by the composition to normalization of tear pH after instillation in the eye is less than 15 .mu.l of 1 M NaOH/mL of composition; iii. the composition is a suspension with the brinzolamide and carboxyvinyl polymer as a suspending agent; iv. the viscosity of the suspension is greater than 20 cps but less than 500 with the viscosity of the suspension being measured at a high shear rate of 120 sec-1 at room temperature; v. the composition is free of any quinolone anti-infective or anti-biotic therapeutic agent; and vi. the pH of the composition is from about 6.2 to about 7.7.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc